Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer.

Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer. - Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052237

Enrollment

100

Registered

2023-09-19

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Patients with clinically suspected pancreatic cancer who are scheduled to undergo EUS-FNA/B regardless of the planned treatment for the pancreas will be enrolled. The collected tissue and cytology spe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with clinically suspected pancreatic adenocarcinoma and scheduled for EUS FNA or EUS FNB, or, patients with pathologically confirmed pancreatic adenocarcinoma and tumor specimen is available. 2. Patients who are at least 18 years of age at the time of consent.

Exclusion criteria

Exclusion criteria: 1. Patients whose participation in this study is decided inappropriate by the principal investigator or subinvestigator. 2. Patients who are strongly suspected to have a specific type of pancreatic cancer based on tumor markers (e.g., IPMC (intraductal papillary mucinous carcinoma), NEN (neuroendocrine neoplasm)).

Design outcomes

Primary

Measure	Time frame
Success rate of KRAS mutation assay, including tumor samples of tissue and cytology and blood samples	—

Countries

Japan

Contacts

Public ContactKumiko Umemoto

St.Marianna University School of Medicine Department of Clinical Oncology

kumemoto@marianna-u.ac.jp+81-44-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026